

UNITED STATE DEPARTMENT OF COMMERCE United States Patent and Trad mark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/303,04	40 04/30,	799 WINSLOW	В	54957-B/JPW/
		,,, <u>,,</u> ¬ □		EXAMINER
HM22/0620 PAMELA G. SALKELD, ESQ.			rk.H	
	•	RPORATION, PATENT DEPA	ART UNIT	PAPER NUMBER
MAILSTOP		ROAD, BUILDING K-6-1	164	=
to be the total the transfer of the total total	in no oron	•	DATE MAILED	06/20/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Applicant

Office Action Summary

ر.

1

Application No. 09/303,040

Applicant(s)

WINSLOW ET AL.

Examiner

HANKYEL T. PARK, PH.D.

Art Unit 1648

The MAILING DATE of this communication appea	rs on the cover sheet with the correspondence address					
 after SIX (6) MONTHS from the mailing date of this community. If the period for reply specified above is less than thirty (30) do be considered timely. If NO period for reply is specified above, the maximum statutor communication. 	CFR 1.136 (a). In no event, however, may a reply be timely filed nication. The statutory minimum of thirty (30) days will be reply within the statutory minimum of thirty (30) days will be reply and will expire SIX (6) MONTHS from the mailing date of this					
	by statute, cause the application to become ABANDONED (35 U.S.C. § 133). the mailing date of this communication, even if timely filed, may reduce any					
	2001					
2a) ☐ This action is FINAL . 2b) ☒ This a	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.						
Disposition of Claims						
4) 💢 Claim(s) <u>37-74</u>	is/are pending in the application.					
4a) Of the above, claim(s) 61-68	is/are withdrawn from consideration.					
5) Claim(s)	is/are allowed.					
6) 💢 Claim(s) 37-60 and 69-74	is/are rejected.					
7)	is/are objected to.					
8)	are subject to restriction and/or election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/a	The drawing(s) filed on is/are objected to by the Examiner.					
11) The proposed drawing correction filed on	☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.					
12) The oath or declaration is objected to by the Exa	The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. § 119						
13) Acknowledgement is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d).					
a) □ All b) □ Some* c) □ None of:						
1. Certified copies of the priority documents have been received.						
. 🗖	ave been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
*See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
·						
Attachment(s) 15) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).					
16) Notice of Preferences Cited (PTO-052)	19) Notice of Informal Patent Application (PTO-152)					
17] Information Disclosure Statement(s) (PTO-1449) Paper No(s) 20) Other:						

Page 2

Application/Control Number: 09/303,040

Art Unit: 1648

DETAILED ACTION

- 1. The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to **Group Art Unit 1648**.
- 2. The request for filing continued prosecution application (CPA) on April 03, 2001 is acknowledged. At the time of filing of the CPA, the previous attorney requested the Office to "enter the unentered amendment previously filed on September 25, 2000." However, the Office never received such an amendment.
- 3. Claims 37-74 are pending. Applicants elect with traverse Group I. Applicants' argument regarding rejoining of Groups I and II and also rejoining of groups III and IV is persuasive; thus, rejoined claims 37-60 and 69-74 of Groups I and II will be examined. Claims 61-68 are withdrawn as nonelected claims.

Claim Rejections - 35 USC § 112

- 4. The following is a quotation of the second paragraph of 35 U.S.C. 112:
 - The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 5. Claims 37-60 and 69-74 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are vague and indefinite in the recitation of

Application/Control Number: 09/303,040 Page 3

Art Unit: 1648

"capable of being expressed", since the term "capable" is not a definitive term. It either expresses or doesn't.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 37-60 and 69-74 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for manipulation of the expression of feline CD86, feline CTLA-4 and their ligands feline CD80 and feline CD86 costimulatory molecules in order to regulate T-cell responses, through augmentation, suppression or redirection, to raise a desired immune response towards a particular feline pathogen or feline disease condition (page 2, lines 30-36), does not reasonably provide enablement for a recombinant virus comprising less than the all the components listed above. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. Applicants have not provided any data in regards to a recombinant virus comprising one foreign nucleic acid that would function as a vaccine as defined in the specification (page 2, line 36 to page 3, line 6). Lacking any convincing evidence to the contrary, Applicants have not enabled the invention.

,

Application/Control Number: 09/303,040

.7

Art Unit: 1648

8. No claim is allowed.

9. Papers relating to this application may be submitted to Group 1600 by facsimile

transmission. Papers should be faxed to Group 1600 located in Crystal Mall 1. The Fax number

for Art Unit 1648 is (703) 308-4426. All Group 1600 Fax machines will be available to receive

transmissions 24 hrs/day, 7 days/wk. Please note that the faxing of such papers must conform

with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the Examiner

should be directed to Hankyel T. Park, Ph.D., whose telephone number is (703) 305-7255. The

Examiner can normally be reached on Monday, Tuesday, Thursday and Friday from 6:30 AM-

4:00 PM, (EST). The Examiner can also be reached on alternate Wednesdays.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's

Supervisor, James C. Housel, can be reached at (703) 308-4027.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Group receptionist whose telephone number is (703) 308-0196.

Hankyel T. Park, Ph.D.

June 16, 2001

IANKYEL T. PARK, PH.D

Page 4

RIMARY EXAMINER